Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ATR12-351 · 1 trial · 1 indication
Incidence, severity, seriousness and relatedness of all treatment-emergent adverse events
| Arm | Type | Description |
|---|---|---|
| Internal controlled arm | EXPERIMENTAL | ATR12-351 on left side of body, vehicle on right side of body in one group; vehicle on left side of body, ATR12-351 on right side of body. |
| Name | Type | Description |
|---|---|---|
| ATR12-351 | DRUG | Topical ointment containing ATR12-351, a LEKTI-secreting strain of S. epidermidis |
Inclusion Criteria: * Adults ≥18 years of age * Confirmed mutation of the serine protease inhibitor of Kazal type 5 (SPINK5) gene * Involvement of ≥20% of body surface area with skin changes consistent with Netherton syndrome Exclusion Criteria: * Use of biologic therapies, antibiotics, antihista...
ATR12-351 is an investigational small molecule being developed for the treatment of Netherton Syndrome, a rare genetic skin disorder. It is administered topically and is currently in clinical development, having completed a Phase 1 trial in adults with the condition.
ATR12-351 is being developed by Azitra Inc, a biopharmaceutical company. Azitra's stock is traded under the ticker symbol AZTR on the stock market.
ATR12-351 is in Phase 1 of clinical development. It is an investigational drug and has not been approved by regulatory authorities. A Phase 1 trial evaluating the drug has been completed.
ATR12-351 has been studied in a completed Phase 1 clinical trial with the identifier NCT06137157, titled 'Evaluation of Topical ATR12-351 in Adults With Netherton Syndrome'. The trial enrolled 6 participants in the United States.
ATR12-351 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial, but it remains in clinical development and has not received approval for commercial use.